Related Experiment Video
Updated: Jan 8, 2026

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
Published on: November 8, 2016
How artificial intelligence can enable personalized mesenchymal stem cell-based therapeutic strategies in systemic
Sushmitha Rajeev Kumar1,2, Khor Kai He1,2, Yogeswaran Lokanathan3
1Malaysia Genome and Vaccine Institute, National Institute of Biotechnology Malaysia, Selangor, Malaysia.
None:
Mesenchymal Stromal Cells (MSCs) are increasingly recognized as promising candidates for treating Systemic Lupus Erythematosus (SLE) due to their immunomodulatory and regenerative properties. However, their therapeutic efficacy remains inconsistent, largely due to the heterogeneity of MSC origins, culture conditions, cell quality, host immune interactions, and the influence of immunosuppressive treatments. Artificial Intelligence (AI) offers powerful tools to address these challenges by optimising MSC modification and application. This review explores how AI can identify optimal genetic and epigenetic targets, predict MSC behaviour under different environmental and priming conditions, and design personalise therapies tailored to individual patients. Moreover, AI enables the analysis of extensive datasets to refine dosing strategies and improve the integration of MSC therapy with immunosuppressants. By enhancing the precision, consistency, and personalisation of MSC-based interventions, AI has the potential to significantly improve therapeutic outcomes in SLE, advancing the field toward more effective and patient-centred autoimmune disease management.
Related Concept Videos
Mesenchymal Stem Cells
iPS Cell Differentiation
EPS and iPS Cells in Disease Research
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Induced Pluripotent Stem Cells
Somatic...

